Literature DB >> 32319730

Neural and behavioral measures suggest that cognitive and affective functioning interactions mediate risk for psychosis-proneness symptoms in youth with chromosome 22q11.2 deletion syndrome.

Samantha R Linton1,2, Abbie M Popa1,2, Steven J Luck3, Khalima Bolden1,4, Cameron S Carter1,4, Tara A Niendam1,4, Tony J Simon1,2.   

Abstract

Behavioral components of chromosome 22q11.2 deletion syndrome (22q), caused by the most common human microdeletion, include cognitive and adaptive functioning impairments, heightened anxiety, and an elevated risk of schizophrenia. We investigated how interactions between executive function and the largely overlooked factor of emotion regulation might relate to the incidence of symptoms of psychotic thinking in youth with 22q. We measured neural activity with event-related potentials (ERPs) in variants of an inhibitory function (Go/No-Go) experimental paradigm that presented affective or non-affective stimuli. The study replicated inhibition impairments in the 22q group that were amplified in the presence of stimuli with negative, more than positive affective salience. Importantly, the anterior N2 conflict monitoring ERP significantly increased when youth with 22q viewed angry and happy facial expressions, unlike the typically developing participants. This suggests that youth with 22q may require greater conflict monitoring resources when controlling their behavior in response to highly salient social signals. This evidence of both behavioral and neurophysiological differences in affectively influenced inhibitory function suggests that frequently anxious youth with 22q may struggle more with cognitive control in emotionally charged social settings, which could influence their risk of developing symptoms of psychosis.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  22q11.2 deletion; emotion regulation; event-related potentials (ERP); executive function; psychosis

Mesh:

Year:  2020        PMID: 32319730      PMCID: PMC9196260          DOI: 10.1002/ajmg.a.61596

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.578


  62 in total

Review 1.  The prefrontal cortex and cognitive control.

Authors:  E K Miller
Journal:  Nat Rev Neurosci       Date:  2000-10       Impact factor: 34.870

2.  EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis.

Authors:  Arnaud Delorme; Scott Makeig
Journal:  J Neurosci Methods       Date:  2004-03-15       Impact factor: 2.390

3.  Lower prepulse inhibition in children with the 22q11 deletion syndrome.

Authors:  Christina Sobin; Karen Kiley-Brabeck; Maria Karayiorgou
Journal:  Am J Psychiatry       Date:  2005-06       Impact factor: 18.112

4.  Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.

Authors:  Ehud Mekori-Domachevsky; Yael Guri; James Yi; Omri Weisman; Monica E Calkins; Sunny X Tang; Raz Gross; Donna M McDonald-McGinn; Beverly S Emanuel; Elaine H Zackai; Gil Zalsman; Abraham Weizman; Ruben C Gur; Raquel E Gur; Doron Gothelf
Journal:  Schizophr Res       Date:  2016-12-29       Impact factor: 4.939

5.  Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome.

Authors:  Doron Gothelf; Carl Feinstein; Tracy Thompson; Eugene Gu; Lauren Penniman; Ellen Van Stone; Hower Kwon; Stephan Eliez; Allan L Reiss
Journal:  Am J Psychiatry       Date:  2007-04       Impact factor: 18.112

6.  Frontostriatal maturation predicts cognitive control failure to appetitive cues in adolescents.

Authors:  Leah H Somerville; Todd Hare; B J Casey
Journal:  J Cogn Neurosci       Date:  2010-09-07       Impact factor: 3.225

7.  An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11.2 deletion syndrome.

Authors:  Kathleen Angkustsiri; Ingrid Leckliter; Nicole Tartaglia; Elliott A Beaton; Janice Enriquez; Tony J Simon
Journal:  J Dev Behav Pediatr       Date:  2012 Nov-Dec       Impact factor: 2.225

8.  A cross-sectional analysis of the development of response inhibition in children with chromosome 22q11.2 deletion syndrome.

Authors:  Heather M Shapiro; Ling M Wong; Tony J Simon
Journal:  Front Psychiatry       Date:  2013-08-07       Impact factor: 4.157

Review 9.  Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

Authors:  Maude Schneider; Martin Debbané; Anne S Bassett; Eva W C Chow; Wai Lun Alan Fung; Marianne van den Bree; Michael Owen; Kieran C Murphy; Maria Niarchou; Wendy R Kates; Kevin M Antshel; Wanda Fremont; Donna M McDonald-McGinn; Raquel E Gur; Elaine H Zackai; Jacob Vorstman; Sasja N Duijff; Petra W J Klaassen; Ann Swillen; Doron Gothelf; Tamar Green; Abraham Weizman; Therese Van Amelsvoort; Laurens Evers; Erik Boot; Vandana Shashi; Stephen R Hooper; Carrie E Bearden; Maria Jalbrzikowski; Marco Armando; Stefano Vicari; Declan G Murphy; Opal Ousley; Linda E Campbell; Tony J Simon; Stephan Eliez
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

10.  Seeing Eye to Eye With Threat: Atypical Threat Bias in Children With 22q11.2 Deletion Syndrome.

Authors:  Abbie M Popa; Joshua R Cruz; Ling M Wong; Danielle J Harvey; Kathleen Angkustsiri; Ingrid N Leckliter; Koraly Perez-Edgar; Tony J Simon
Journal:  Am J Intellect Dev Disabil       Date:  2019-11
View more
  2 in total

Review 1.  A cross-comparison of cognitive ability across 8 genomic disorders.

Authors:  Michael Mortillo; Jennifer G Mulle
Journal:  Curr Opin Genet Dev       Date:  2021-05-31       Impact factor: 4.665

2.  Atypical response inhibition and error processing in 22q11.2 Deletion Syndrome and schizophrenia: Towards neuromarkers of disease progression and risk.

Authors:  Ana A Francisco; Douwe J Horsthuis; Maryann Popiel; John J Foxe; Sophie Molholm
Journal:  Neuroimage Clin       Date:  2020-07-17       Impact factor: 4.881

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.